BIDAI Recruits Expert from German Biotech 'Medizen'..."Establishing Bio Advisory Committee"

[Asia Economy Reporter Hyunseok Yoo] VidiAi announced on the 17th that it will appoint Park Sewon, Science Advisor of the German listed company Medizen, as an outside director.

Advisor Park is a clinical veterinarian graduate from Seoul National University College of Veterinary Medicine and formerly served as a veterinary professor at Tufts University in the United States. At Medizen, the first German biotech company to succeed in new drug development, he has been serving as the Science Advisor for the Korean division.

Prior to this, in February, VidiAi signed a joint development partnership with PlatBio, led by Dr. Kim Seonjin, known as the top authority among clinical implementation experts. Regarding the anticancer new drug under development at Allison Pharmaceuticals in the U.S., VidiAi plans to appoint Dr. Kim Seonjin as an executive officer to establish future clinical plans and pursue multifaceted cooperation such as acquiring domestic new drug development companies.

A VidiAi official stated, “To strengthen the bio business sector, which is one of the new growth engines, we plan to actively recruit bio experts and form a Science Advisory Board. Internally, we will also improve organizational efficiency by reallocating related personnel to maximize the improvement of corporate value through the bio sector.”

He added, “Last year, we showed poor performance due to one-time cost increases such as increased allowance for doubtful accounts on trade receivables and losses on convertible bond derivatives. However, this year, we will strive to improve profitability through profitability-focused management of the existing core power plant business, increased profit contribution from the renewable energy business sector, and revitalization of the bio business.”

This content was produced with the assistance of AI translation services.